Abstract
Introduction β 3 -adrenoreceptor (β 3 AR) is a G-protein coupled receptor (GPCR) discovered and cloned in the 1980s [1] [2] [3] . Early studies demonstrated that human β 3 AR is expressed primarily in both white and brown adipocytes where regulates lipolysis and thermogenesis [2] . More recent reports indicate that β 3 AR is also expressed in human heart, gallbladder, gastrointestinal tract, prostate and urinary bladder detrusor, brain as well as in near-term myometrium [4] .
We recently showed, for the first time that, the β 3 AR is also expressed in different nephron segments of mouse kidney. In the cortical and outer medullary collecting duct, β 3 AR shares its localization with the vasopressin type-2 receptor (AVPR2), whose activation by vasopressin (AVP) is critical for the shuttling of the water channel aquaporin 2 (AQP2) at the apical plasma membrane, increase of water reabsorption and, ultimately, antidiuresis. We proved, in fact, that short-term β 3 AR selective agonism promoted a potent antidiuretic effect in mice lacking AVPR2 [5] .
These results are relevant when considering β 3 AR as a potential drug target for the treatment of X-linked Nephrogenic Diabetes Insipidus (X-NDI) [6] [7] [8] [9] , a congenital disease caused by inactivating mutations of the AVPR2 and consequential lack of AVP-induced antidiuresis.
To consider a possible chronic use of β 3 AR agonists as therapeutic approach for X-NDI it is mandatory to evaluate whether and when the receptor undergoes desensitization switching off its downstream signaling with reduction of agonist response and clinical efficacy of the drug. In general, desensitization of a GPCR results in decreased responsiveness to repeated or chronic exposure to agonist. Desensitization mechanisms include: 1) receptor uncoupling from downstream signal transduction elements mediated by kinases; 2) receptor internalization; 3) receptor down-regulation via increased degradation and/or reduced synthesis [10] [11] [12] .
It is well established that agonist-promoted desensitization of both β 1 -and β 2 -adrenoreceptors is mainly due to phosphorylation of the receptors by several kinases including the β adrenoreceptor kinase (βARK) and the cAMP-dependent protein kinase A (PKA) [13] [14] [15] . β 3 AR, unlike β 1 -and β 2 -AR, lacks the target amino acid sequences for βARK and PKA in the cytoplasmic C-terminus.
Consequently, β 3 AR should be less susceptible to PKA/βARK-mediated receptor recycling and desensitization in response to hyperstimulation [16] [17] [18] .
Still, the question whether the β 3 AR is subject to desensitization is a matter of debate. On one hand, it has been shown that β 3 AR transfected into Chinese hamster ovary (CHO) cells [14, 19, 20] , murine L fibroblast cells and chinese hamster fibroblast (CHW) cells [18, 21] or endogenously expressed in human SK-N-MC neuroblastoma cells [16] was resistant to both short-and long-term agonist-induced desensitization. Experiments to investigate desensitization in rodent adipose tissue did not shed a light on this controversial picture [13, [22] [23] [24] [25] . On the other hand, agonist-induced β 3 AR desensitization was demonstrated in mouse ileum [24] and with human embryonic kidney (HEK) cells transfected with β 3 AR [14, 26] .
Overall, these findings suggest that agonist-induced desensitization of β 3 -adrenoceptors occurs in a tissue-or cell type-dependent manner [27] .
Therefore, the present study was designed to specifically explore human β 3 AR desensitization dynamics in renal collecting duct epithelial cells, which have not been described so far. The evaluation of long-term desensitization could be important for unveiling the potential tachyphylaxis occurring during chronic treatment of X-NDI with β 3 AR agonists. In this respect, we analyzed signal transduction pathways, membrane trafficking and expression level of β 3 AR chronically stimulated with the specific agonist mirabegron which has been already introduced into the clinic for treatment of overactive bladder syndrome [28, 29] . To this end, we stably expressed the β 3 AR tagged with mCherry in mouse collecting duct M-1 cells [30] and compared these results with data from M-1 cells expressing human AVPR2, whose desensitization dynamics were well characterized in the collecting duct [31] [32] [33] [34] .
Here, we found that β 3 AR is less prone than AVPR2 to agonist-induced desensitization in renal collecting duct epithelial cells, showing sustained cAMP production, persistent membrane localization and delayed degradation under long-term agonist exposure. Of note, the sustained cAMP signaling induced by β 3 AR activation deeply impact AQP2 membrane localization, which is continuously expressed on the apical membrane for up to 12 h.
These results encourage preclinical studies supporting the hypothesis that chronic mirabegron treatment could promote a durable antidiuretic effect in X-NDI patients.
Materials and Methods
Antibodies and Reagents 1-deamino-8-D-arginine vasopressin (dDAVP, cat.# V-1005) and cycloheximide (cat.# c1988) were from Sigma (www.sigmaaldrich.com), while mirabegron (cat.# sc211912) was from Santa Cruz Biotechnology (www.scbt.com). Mouse monoclonal anti-Na + /K + -ATPase α-1 antibody (cat.# 05-369) was from Millipore (www.merckmillipore.com), rabbit anti-mCherry (cat.# ab167453) from Abcam (www.abcam.com) and polyclonal anti-FLAG® (cat.# F7425) from Sigma. The rabbit affinity-purified polyclonal antibody against human AQP2 was previously described [35] .
cDNA constructs of β 3 AR-mCh/ FLAG® and AVPR2-mCh Human β 3 -adrenoreceptor (β 3 AR), cloned in pcDNA3.1 plasmid, and human vasopressin type 2 receptor (AVPR2), cloned in pRP vector, were from ThermoFisher (www.thermofisher.com) and Cyagen (www.cyagen.com), respectively. The fluorescent tag mCherry was attached to the carboxy-terminus of both receptors. The human β 3 AR cloned in pRP vector tagged with FLAG® at C-terminus was from Cyagen.
Cell culture and transfection
Mouse cortical collecting duct M-1 cells [30] and MCD4 cells, a clone of M-1 cells stably transfected with human-AQP2, were cultured as described elsewhere [36, 37] . To obtain stable cell lines expressing β 3 ARmCh (M-1-β 3 AR-mCh and MCD4-β 3 AR-mCh) or AVPR2-mCh (M-1-AVPR2-mCh and MCD4-AVPR2-mCh) cells were transfected using Lipofectamine® 2000 (www.thermofisher.com) and the appropriate construct according to the manufacturer's instructions. After 14-20 days of selection in medium containing 500 µg/ml hygromicin B (www.thermofisher.com), resistant colonies were isolated with cloning rings and expanded to evaluate expression and membrane localization of β 3 AR-mCh or AVPR2-mCh. In parallel experiments M-1 cells were transiently transfected using Lipofectamine® 2000 with β 3 AR-FLAG®.
FRET-based measurement of cAMP/PKA in single cells
The FRET-based cAMP sensor Epac H96 [38] was a generous gift of Prof. Kees Jalink (Netherlands Cancer Institute, Amsterdam, Netherlands). AKAR4 [39] was kindly provided by Prof. Jin Zhang (John Hopkins University School of Medicine, Baltimore, MD). Cells were seeded on Ø 25 mm glass coverslips and transiently transfected with Epac H96 or AKAR4 using Lipofectamine® 2000 (www.thermofisher. com). Cells were mounted in a perfusion chamber (FCS2 Closed Chamber System, www.bioptechs.com) and imaged using 40× Plan Fluor (NA 1.30) oil immersion objective lens. An Hepes-buffered Ringer's solution was used to perfuse cells during the experiment, containing: 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM Hepes, 5 mM Glucose, 1.0 mM CaCl 2 , pH 7.4.
Real-time FRET imaging experiments were performed at room temperature using a fluorescence ratio imaging system built around a TE2000-S inverted fluorescence microscope equipped with a cooled CCD camera (CoolSNAP HQ, www.photometrics.com). MetaFluor software (www.moleculardevices.com) was used to acquire ratio data. FRET emission ratios (535 nm/485 nm, 440 nm excitation) were acquired every 5 s. The fluorescence of mCherry (excitation 585 nm, emission 610 nm) did not interfere with any of these measurements [40] . Figures depict data from 5-8 cells summarized for each experiment; at least four independent runs were conducted. Data are expressed as means ± SEM. Steady state FRET experiments were performed to measure intracellular cAMP levels in single cells using Epac H96 [38] , as previously described [35, 41] .
Briefly, M-1-β 3 AR-mCh and M-1-AVPR2-mCh cells were grown onto Ø 25 mm glass coverslips at 37°C and transfected with Epac H96 using Lipofectamine® 2000. 12 hours before the experiment cells were treated overnight with 50 µM indomethacin, a cyclooxygenase inhibitor, to prevent the increase in basal cAMP concentration due to autocrine/paracrine stimulation of P2-purinergic receptors [42, 43] , as previously reported [36] . M-1-β 3 AR-mCh and M-1-AVPR2-mCh cells were either left under basal condition or stimulated for 1 h at 37°C with increasing doses of mirabegron or dDAVP: 1 nM, 10 nM, 100 nM and 1 µM.
To evaluate the effect of long-term stimulation of β 3 AR-mCh/FLAG® or AVPR2-mCh on cAMP production, Epac H96-expressing cells were pretreated for 30 min with 10 µg/ml cycloheximide, a protein synthesis inhibitor, to prevent the potential contribution of newly synthesized receptor. Cells were either left under basal condition or treated with 10 nM mirabegron or 100 nM dDAVP for 1, 3 ,6, 12 and 24 h at 37°C in presence of 10 µg/ml cycloheximide. After stimulation, cells were fixed in PBS containing 4% paraformaldehyde and mounted on glass slides.
Steady state FRET measurements were carried out using MetaMorph software (www.moleculardevices. com). Data from 15 different fields, each one containing at least 3 H96-expressing cells, were summarized for a single coverslip/treatment, and at least three independent coverslips were blind-analyzed. Averaged netFRET values from the different experimental conditions were normalized as percentage of the netFRET of unstimulated cells. netFRET data were analyzed using Prism software (version 5.0; www.graphpad.com). Unpaired data were assessed for statistical significance using the Student's t test. Data are expressed as means ±SEM and P <0.05 was considered statistically significant.
Evaluation of cytosolic levels with Fura-2 For intracellular Ca
2+ measurements, M-1-β 3 AR-mCh or M-1-AVPR2-mCh cells were seeded on glass coverslips (Ø 25 mm). Ringer's Solution was used to perfuse cells during the experiment containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM Hepes, 5 mM Glucose, 1.0 mM CaCl 2 , pH 7.4. Cells were loaded with 5 µM Fura-2 (www.thermofisher.com) for 25 min at 37°C in DMEM. Coverslips with dye-loaded cells were analyzed with a set-up described in detail in previous papers of our group [41, 44, 45] . Fluorescence measurements were performed using Metafluor (www.moleculardevices.com). After background images correction, Fura-2 ratio was normalized to an average 2 min. baseline (R0) before agonist addition to obtain the relative R/R 0 . Figure depict 4 different cells of the same coverslip, at least four independent runs were conducted.
Immunofluorescence
As already described for steady-state FRET experiments, M-1-β 3 AR-mCh/FLAG®, MCD4-β 3 AR-mCh, M-1-AVPR2-mCh or MCD4-AVPR2-mCh cells were treated with 10 µg/ml cycloheximide and stimulated for 1, 3 ,6 and 12 h with 10 nM mirabegron or 100 nM dDAVP, respectively. Cells treated with 10 µg/ml cycloheximide alone for 30 min were considered as resting condition. Cell monolayers were then fixed in PBS containing 4% paraformaldehyde (M-1-β 3 AR-mCh/ FLAG® and M-1-AVPR2-mCh cells) or methanol (MCD4-β 3 AR-mCh and MCD4-AVPR2-mCh cells) and washed twice with PBS. Cells were blocked with 1% BSA in PBS, then anti-Na + /K + -ATPase α-1 antibody and anti-FLAG® (for M-1-β 3 AR-mCh/FLAG® and M-1-AVPR2-mCh) or anti-AQP2 antibody (for MCD4-β 3 AR-mCh and MCD4-AVPR2-mCh cells) were incubated for 2 h at room temperature. The bound antibodies was detected with Alexa Fluor secondary antibodies (www.thermofisher.com). Images were acquired with a Leica TCS-SP2 confocal microscope (www.leicamicrosystems.com).
Western blotting
These experiments were performed in presence of 10 µg/ml cycloheximide, as reported above. M-1-β 3 AR-mCh and M-1-AVPR2-mCh cells grown in 6-well culture plates were either left under basal condition or treated for 1, 3 ,6, 12 and 24 h at 37°C with 10 nM mirabegron or 100 nM dDAVP, respectively. Cells were washed twice with ice-cold PBS w/o Ca 2+ and Mg 2+ and scraped into RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA) containing protease and phosphatase inhibitors (1 mmol/l phenylmethylsulfonyl fluoride, 10 mmol/l leupeptin, 1 mg/ml pepstatin A, 10 mmol/l NaF, 1 mmol/l sodium orthovanadate, and 15 mmol/l tetrasodium pyrophosphate). Lysates were then Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry sonicated for 30 seconds at 4°C using a microprobe sonicator. Insoluble material was pelleted at 13, 000 g for 30 min at 4°C. 5 µg of each supernatant was separated by standard SDS-PAGE using Mini-PROTEAN® TGX Stain-Free™ Precast Gels Bio-Rad and analyzed by Western blotting as previously described [46] . Densitometry was performed using the Image Lab™ software (Bio-rad) bundled with ChemiDoc™(Bio-Rad) imaging system, after normalization for the total protein loading using the Stain-Free™ technology (BioRad) according to manufacturer's instructions.
Results
β 3 AR activation elevates intracellular cAMP levels, activates PKA and increases Ca 2+ in renal epithelial cells At first, we studied the β 3 AR signaling in M-1 cells stably expressing the receptor tagged with mCherry (M-1-β 3 AR-mCh, Fig. 1A ). β 3 AR is mainly localized on the plasma membrane, thus putatively able to sense and respond to extracellular stimuli. Thus, to asses β 3 AR intracellular signaling, we evaluated cAMP generation and PKA activity in M-1-β 3 AR-mCh cells by expressing, either the cytosolic cAMP sensor Epac H96 [38] or the PKA activity probe AKAR4 [39] , respectively. Both sensors are FRET-based, however, while Epac H96 works on the principle of "loss of FRET" and its FRET ratio decreases in response to cAMP elevation, AKAR4 works based on "gain of FRET" and reaches maximum FRET ratio when PKA activity is high [47] . Fig. 1 shows that treatment with 10 nM mirabegron, a selective human β 3 AR agonist, induced a decrease in the FRET ratio of H96 (Fig. 1B) and a parallel increase in the FRET ratio of AKAR4 (Fig. 1C) , indicating increases of both cAMP level and PKA activity only in M-1-β 3 AR-mCh cells (white triangles) compared to untransfected cells (black diamonds).
In addition, we investigated whether mirabegron triggers Ca 2+ oscillations. 
Dose-dependent response to Mirabegron of M-1-β 3 AR-mCh cells
Epac H96 was also used in steady-state FRET experiments to determine the lowest dose of mirabegron able to induce a significant cAMP production in M-1-β 3 AR-mCh cells ( Fig. 2A) . One-hour exposure to mirabegron (1 nM, 10 nM, 100 nM or 1 µM) induced a significant cAMP production, when compared to unstimulated cells, for all the tested doses. 10 nM was the lower dose inducing maximal cAMP generation. Accordingly, we used 10 nM mirabegron throughout this study.
Parallel experiments were performed in M-1-AVPR2-mCh cells to evaluate the minimum effective dose of dDAVP, a selective AVPR2 agonist. Fig. 2B shows that intracellular cAMP levels did not significantly change after treatment with 1 nM and 10 nM dDAVP while cAMP production was maximal upon exposure to 100 nM dDAVP, as already reported [32, 48, 49] , which was hence the concentration used for all the following experiments.
Sustained receptor stimulation does not turn off the β 3 AR signaling
Next, we evaluated if long-term exposure to mirabegron desensitizes β 3 AR in term of cAMP signaling in M-1-β 3 AR-mCh cells expressing Epac H96. We calculated steady state netFRET changes as index of the cAMP production induced by mirabegron over different time points (1, 3, 6, 12 and 24 hours). All experiments were performed in presence of cycloheximide to inhibit protein synthesis and thus excluding the potential contribution of newly synthesized receptors to cAMP production.
Compared to resting cells (cycloheximide, Fig. 3A ), the netFRET signal was significantly reduced (of about a 30%) in M-1-β 3 AR-mCh cells treated with mirabegron for 1 h, indicating cAMP generation. This significant decrease of netFRET was also observed in cells exposed to mirabegron up to 12 hours. These findings indicate long-term, continuous cAMP signaling in the presence of mirabegron and suggest that no β 3 AR desensitization occurred within 12 h. To check whether this sustained response could be an artifact due to the presence of the mCherry tag, we repeated the same experiment in M-1 cells transiently transfected with FLAG®-β 3 AR (M-1-β 3 AR-FLAG®, Fig. 3B ). The results obtained with the two β 3 AR constructs were overlapping.
Parallel experiments performed on M-1-AVPR2-mCh cells showed that 1h exposure to dDAVP elicited a significant reduction in netFRET when compared to untreated cells (cycloheximide, Fig. 3C ). This netFRET reduction was of the same extent of that induced by mirabegron in M-1-β 3 AR-mCh/ FLAG® cells, indicating similar cAMP signaling after 1h of agonist exposure in both cell lines. However, dDAVP stimulation longer that 1h did not induce any significant netFRET reduction. This evidence likely suggested that β 3 AR was less prone than AVPR2 to undergo long-term agonist-induced desensitization in renal collecting duct.
Plasma membrane localization of β 3 AR under chronic agonist stimulation in renal epithelial cells
Next, we analyzed the cellular distribution of the receptor in M-1-β 3 AR-mCh cells upon chronic stimulation with mirabegron in the presence of cycloheximide to exclude 
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Cellular Physiology and Biochemistry the contribution of newly synthesized receptor (Fig. 4) . Confocal microscopy experiments showed that at rest, β 3 AR was mainly localized at the basolateral plasma membrane where it largely colocalized with the plasma membrane marker Na + /K + -ATPase. After 1 h stimulation with mirabegron, no apparent receptor internalization was observed since β 3 AR still largely co-localized with Na + /K + -ATPase. At later time points of continuous mirabegron stimulation (3, 6 and 12 h), a modest internalization of the receptor into a cytosolic punctate pattern appeared. However, β 3 AR was still predominantly localized at the basolateral plasma membrane, even after 12 h of exposure to mirabegron. To check whether the reduced endocytosis could be explained by the presence of the mCherry tag, we repeated the same experiment with M-1-β 3 AR-FLAG® (Fig. 5) . The results obtained with the two β 3 AR tags were overlapping.
In parallel experiments, we analyzed the receptor membrane trafficking in M-1-AVPR2-mCh cells. We found that under basal conditions, the AVPR2 was mostly localized at the plasma membrane. In contrast, as shown in Fig. 6 , exposure to dDAVP caused a robust and time-dependent internalization of AVPR2, as evidenced by appearance of packed cytoplasmic vesicles (Fig. 6 ). These effects were already observed at 1 h of incubation with dDAVP. Receptor internalization was more dramatic at later time points and most of the receptors localized within cytoplasmic vesicles rather than at the plasma membrane. In addition, 12 h of continuous exposure to dDAVP led to a strong reduction of AVPR2 signal, probably indicating receptor degradation.
These findings indicated that, unlike AVPR2, β 3 AR did not internalize under chronic agonist stimulation in renal epithelial cells.
Long-term receptor stimulation causes delayed downregulation of β 3 AR protein in renal collecting duct epithelial cells
Long-term exposure to agonists can cause receptor downregulation, which is characterized by the depletion of the cellular receptor content due to alterations in the rate of receptor degradation and/or synthesis [12] . Here, Western blot experiments were performed in the presence of cycloheximide.
As shown in Fig. 7A anti-mCherry antibodies revealed a band of about 70 kDa for the chimeric β 3 AR-mCh. Compared to resting cells (cycloheximide alone), comparable levels of the receptor were observed at 1 and 3 h, while a small reduction of β 3 AR-mCh (of about 20%) was observed at 6 and 12 h of continuous receptor activation (Fig. 7B) . These results likely indicated that β 3 AR-mCh expression was slightly affected by long-term exposure to mirabegron up to 12 hours. Indeed, chronic exposure to mirabegron induced about 70% of receptor downregulation only after 24 h (Fig. 7B) . µg/ml cycloheximide (resting) or stimulated with 100 nM dDAVP 1, 3, 6 and 12 hours in presence of 10 µg/ml cycloheximide. AVPR2 (red) localization was analyzed directly using confocal microscopy. Na + / K + -ATPase (green) was used as plasma membrane marker. Already after 1 h dDAVP, AVPR2 was internalized. At 3 and 6 hours after dDAVP exposure AVPR2 was lost from the plasma membrane and at 12 h receptor membrane staining was strongly reduced, probably because the sustained stimulation of AVPR2 induced receptor degradation. Images are representative of 3 independent experiments. Scale bars, 20 μm.
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Conversely, in M1-AVPR2-mCh cells, the anti-mCherry antibody revealed a broad smear around 70 kDa and lower bands between 70 and 50 kDa (Fig. 7C) . In presence of dDAVP, the intensity of higher molecular mass bands, representing the mature form of the protein, was reduced in a time-dependent manner. As reported in Fig. 7D , a strong reduction of about 70% was clearly evident even after 3 h exposure to dDAVP and increased at later time points (6 and 12 h). At 24 h of stimulation with dDAVP the mature form of the receptor was undetectable while the intensity of the lower molecular mass bands, likely representing degradation products of AVPR2, was greatly increased, thus suggesting complete degradation of AVPR2.
These finding indicates that β 3 AR was resistant to degradation up to 12 h of continuous exposure to the agonist.
β 3 AR activation promotes apical AQP2 expression in renal epithelial cells
In renal collecting duct cells, cAMP levels are fundamental regulators of AQP2 translocation to the apical plasma membrane [46] . Therefore, the fact that β 3 AR chronic stimulation sustains persistent high levels of cytosolic cAMP should be taken into account when considering AQP2 translocation. Thus, we investigated the effect of long-term β 3 AR activation on AQP2 trafficking in MCD4 cells, a clone of M-1 cells that stably express human-AQP2 [50] . These cells were stably transfected with the cDNA that encodes either β 3 AR-mCh or AVPR2-mCh. Fig. 8A reports the confocal analysis of AQP2 localization in MCD4-β 3 AR-mCh resting cells after treatment with mirabegron for 1, 3, 6, 12 hours. The cAMP-elevating agent forskolin (FK) was used as positive control for its ability to promote AQP2 exocytosis. AQP2 staining was imaged in a xy confocal plan, passing through the cell apical membrane (upper panel) and in the xz confocal plan. In unstimulated MCD4-β 3 AR-mCh cells (cycloheximide alone), most of the AQP2 was located in intracellular and sub-apical vesicles. 1 h mirabegron treatment resulted in AQP2 redistribution to the apical plasma membrane similar to that obtained by maximal FK stimulation. Interestingly, even at 12 hours of continuous stimulation of β 3 AR with mirabegron AQP2 was still exposed at the apical plasma membrane clearly indicating that β 3 AR intracellular signaling is not switched off. These results were consistent with our findings on persistent increase of intracellular cAMP, slow internalization and delayed downregulation of β 3 AR in M-1 cells. On the contrary, the effect of dDAVP on AQP2 translocation in MCD4-AVPR2-mCh cells was observed within 3 h (Fig. 8B) . As described previously in this study, this evidence was due to a short-lasting cAMP signaling, rapid internalization and downregulation of AVPR2 which already occurred at 3 hours of dDAVP stimulation.
Discussion
Maintaining water homeostasis lies in the ability of the kidneys to concentrate urine and can be mainly attributed to the AVP/AVPR2/AQP2 axis [51] . Under physiological conditions, excessive loss of water through the urine is prevented by the AVP which promotes the osmotic reabsorption of water in the collecting ducts. In kidney collecting duct principal cells, the binding of AVP to basolateral AVPR2 triggers the activation of adenylyl cyclase via Gαs protein, with generation of cAMP that in turn activates protein kinase A (PKA). Consequently, the AQP2 is phosphorylated and translocated from a pool of intracellular storage vesicles to the apical plasma membrane of the principal cells, where it highly increases membrane permeability promoting water reabsorption [52] . This process is reversed by a reduction in circulating AVP levels, which reflects the establishment of isotonicity.
Inactivating mutations of AVPR2 cause X-linked Nephrogenic Diabetes Insipidus (X-NDI). The lack of functional AVPR2 impairs both AQP2 trafficking to the plasma membrane and its transcription in X-NDI patients [53] . Therefore, the kidney loses its ability to concentrate urine leading to the production of large volumes of dilute urine.
Several studies suggested the possibility to restore proper water homeostasis in X-NDI by activating other Gs-coupled receptors expressed in the same renal cells expressing defective AVPR2 [5, 46, [54] [55] [56] . However, the potential use of the GPCR exploited so far, such as secretin [46] , calcitonin [54] and EP4 [55, 56] , is limited by their rapid desensitization [57] [58] [59] .
In this respect, β 3 AR seems to be a promising drug target to promote antidiuresis bypassing AVPR2 signaling. β 3 AR is localized in the AVP-sensitive nephron segments and its activation by a single intraperitoneal injection of BRL3744 induces antidiuresis in mice lacking AVPR2 [5] . Since X-NDI is a congenital condition, long-term treatment with β 3 AR agonists may be considered as one of therapeutic possibilities. Thus, as a pre-requisite to predict the feasibility of future clinical trials, we first evaluated in vitro whether β 3 AR is subject to desensitization upon chronic stimulation in renal cells.
Here, long-term desensitization was investigated with respect to receptor downstream signaling, internalization and degradation.
We first evaluated the signaling pathway through which β 3 AR signals in renal cells. In the present study, we showed that mirabegron-induced β 3 AR activation, elevated intracellular cAMP and activates PKA. These results are consistent with our recent study in which, in mouse kidney tubule suspensions, treatment with specific agonist for mouse β 3 AR led to a concentration-dependent increase in intracellular cAMP [5] . In addition, we show that mirabegron induced not synchronous Ca 2+ transients in kidney cells expressing β 3 AR. These results are in line with previous reports on the intracellular Ca 2+ mobilization triggered by cAMP-mediated agonists, including AVP and dDAVP [60] [61] [62] [63] . Furthermore, previous studies pointed out a key role for localized increases in intracellular Ca 2+ concentration as trigger for the fusion of vesicles to their target membranes [16] , as also reported for the AVP-dependent exocytotic insertion of AQP2 [63] . Thus, mirabegron-induced Ca 2+ increases might be important for the fusion of AQP2 vesicles to the apical membranes.
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In the present study, β 3 AR showed preserved cAMP signaling even after 12 h of continuous agonist exposure. Different studies indicated that long-term activation of β 3 AR (up to 24 h) induced adenylyl cyclase activity [14, 20] and cAMP signaling [19] that were, however, significantly reduced over the time course of the experiments. Considering the small amount of receptor internalization, the sustained increase in cAMP level under chronic activation of β 3 AR is likely due to the functional receptor localized at the basolateral membrane and not within the endocytic pathway, as reported for other GPCRs [48, 64, 65] . In addition, the small reduction in the expression level of β 3 AR after 6 h probably indicates that internalized β 3 AR undergoes degradation. Previous independent studies showed that, in chinese hamster fibroblasts (CHW) cells expressing β 3 AR [17, 66] , the receptor density on the plasma membrane was unchanged after 24 h treatment with isoproterenol. However, both studies were performed in the absence of cycloheximide, thus membrane insertion of newly synthesized receptor cannot be excluded. However, these evidences seemed strictly dependent by the cell type since, under the same chronic stimulation, β 3 AR was significantly reduced in murine L fibroblast cells and human neuroblastoma SK-N-MC cells [66, 67] .
Overall, these findings strongly suggested that, at least in vitro, human β 3 AR is resistant to chronic agonist-induced desensitization in renal cells. Of note, this effect is not an artifact due to the presence of the large mCherry tag, since same results were also obtained with the small FLAG® tag (see Fig. 3B and 5) .
In addition, we demonstrated that long-term β 3 AR stimulation with mirabegron, leading to persistent higher levels of cytosolic cAMP, keeps promoting AQP2 apical membrane expression up to 12 h in renal cells. The persistent effect on the AQP2 apical localization likely supports the hypothesis that chronic β 3 AR agonist use could be exploited to promote water reabsorption for the long time in vivo. It should be noted that β 3 AR agonists are already approved by the American food and drug administration (FDA) and the European Medicines Agency (EMA) for the treatment of overactive bladder (OAB) and mirabegron is the first drug licensed for this use [68, 69] . It is a safe, effective and well-tolerated new class of drug [70] [71] [72] [73] . Considering the expression of β 3 AR in the heart, it has been demonstrated, by several studies, that mirabegron does not cause clinically relevant changes in cardiovascular safety [73] .
In our study, parallel experiments regarding AVPR2 highlighted the substantial desensitization differences between AVPR2, selected by the evolution as the main mediator of the antidiuretic action in the kidney and β 3 AR, an alternative GPCR proposed to mimic AVPR2 effects.
We show here that AVPR2 was largely sequestrated within intracellular vesicles and strongly downregulated with no significant downstream signaling after 3 h exposure to dDAVP. In fact, physiological effects of AVPR2 are very rapid and promptly reversible [74] . Vasopressin has a very short biological half-life, about 3 min [74] , and exhibit robust circadian oscillations increasing osmolality and decreasing volume of the urine during sleep to prevents nocturnal polyuria and sleep disruptions [75] . These mechanisms are likely preserved in X-NDI patients, although the absence of functional AVPR2 prevents a proper antidiuresis. Therefore, stimulation of another GPCR expressed in kidney principal cells, might circumvent the AVPR2 defect. Of note, β 3 AR is less prone than AVPR2 to agonist-induced desensitization in renal collecting duct epithelial cells and its chronic stimulation promoted a continuous effect on AQP2 apical expression. These findings encourage preclinical studies supporting the hypothesis that chronic β 3 AR stimulation should promote effective antidiuresis in X-NDI patients.
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